KraneShares MSCI All China Health Care Index ETF (KURE)

KURE is an exchange-traded fund that gives investors exposure to Chinese healthcare and pharmaceutical companies through the MSCI China Health Care Index. It is a specialized vehicle for those seeking to own a specific sector — healthcare and life sciences — within China’s heavily regulated, state-influenced stock market. Healthcare in China has grown into a substantial industry, but the regulatory environment is volatile and the political risk is real, making this fund a concentrated and often illiquid bet rather than a broad market play.

The fund is issued by KraneShares, a specialist manager in thematic and geographically focused ETFs, and it trades on the NASDAQ under the ticker KURE. Like all ETFs, it is a basket of holdings that tracks an underlying index and trades during market hours like a stock. The MSCI China Health Care Index itself contains roughly 20–50 companies across pharmaceuticals, medical devices, healthcare services, and biotechnology — the exact composition shifts as index methodologists rebalance and as regulatory changes alter which companies qualify. Holdings typically include both listed mainland Chinese companies (A-shares and H-shares) and Hong Kong-listed subsidiaries, a structure that reflects how Chinese healthcare firms navigate China’s capital controls.

The core appeal of healthcare-focused China exposure is that health spending in China has risen sharply alongside the country’s aging population and rising middle-class incomes. Chinese pharmaceutical firms and device manufacturers operate in a much larger, faster-growing market than a decade ago. But ownership of this fund comes with specific risks that are quite different from owning a broad China index or a healthcare fund focused on developed markets.

The first is regulatory risk, which is severe. In 2018 and 2020, the Chinese government introduced unexpected price controls and restrictions on the drug companies it regulates, and the National Medical Products Administration has continued to tighten approval and reimbursement rules. A single regulatory announcement — whether pricing controls, restrictions on advertising, or changes to which drugs the government will cover — can reshape the economics of entire sub-sectors overnight. Foreign investors have no ability to influence these decisions and often learn about them only after market impact.

The second is liquidity. While the largest healthcare companies in China are reasonably liquid on their home exchanges, KURE’s smaller holdings may have limited trading volume, which can widen the gap between the fund’s stated net asset value and the price you pay or receive when buying or selling shares. This is especially true during periods of market stress, when volume typically dries up.

The third is concentration risk. A healthcare index for any single country is narrower than a broad market index, and a single-country healthcare index in an emerging market is narrower still. A handful of large pharmaceutical or biotech firms dominate the holdings, and company-specific news — failed drug trials, executive changes, compliance actions — carries outsized weight.

Finally, there is currency risk. The underlying holdings trade in Chinese yuan, Hong Kong dollars, or Chinese yuan-denominated shares (A-shares). When the exchange rate between those currencies and the US dollar shifts, an American investor’s returns shift with it, independent of how the companies themselves perform. During periods of capital flight or geopolitical tension, the yuan often weakens, which can dampen returns for dollar-based investors.

Like all ETFs, KURE carries an expense ratio — the annual fee that KraneShares charges for managing the fund — and that ratio is generally higher than a broad-based US or global index fund would charge, reflecting the specialized nature and smaller asset base of a sector-focused, emerging-market vehicle. The fund trades with fairly tight bid-ask spreads during normal market conditions, though not as tightly as a mega-fund tracking the S&P 500 would.

KURE is not a fund for core portfolio exposure or for someone seeking simple, low-cost China market exposure. It is a tool for investors who have done the work to understand Chinese healthcare economics, who have conviction about the sector’s long-term growth, and who are comfortable bearing regulatory and concentration risk in exchange for a targeted bet. For anyone researching the fund, the prospectus and the MSCI China Health Care Index methodology document are the essential reads, along with close attention to Chinese regulatory developments and the quarterly SEC filings the fund publishes. The healthcare sector in China is real and growing, but this fund is a specialized, volatile vehicle that demands active knowledge to use well.